MTIG, Focused on Microbiome-based Therapies, Adds Alveolus to Group

MTIG, Focused on Microbiome-based Therapies, Adds Alveolus to Group

311845

MTIG, Focused on Microbiome-based Therapies, Adds Alveolus to Group

The Microbiome Therapeutics Innovation Group (MTIG), a coalition of companies working to develop U.S. Food and Drug Administration (FDA)-microbiome-based therapies, announced the addition of Alveolus Bio to its group. Alveolus has more than a decade of research into neutrophilic inflammation — an asthmatic inflammation driven by specific white blood cells called neutrophils — and microbial dysbiosis, or an imbalance in bacteria composition. Its therapy development program focuses on a range of lung diseases occurring throughout…

You must be logged in to read/download the full post.